Re: What's the deal with Zenith?
in response to
by
posted on
Jun 23, 2023 12:10PM
Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
KOO - I don't buy what you and jonzobot have said about screwing up Zenith. It wouldn't hurt Zenith at all. It would take an asset that is basically worth nil and either create value in it or it would stay worth nil. Where is the huge downside you allude to? Either way, Zenith will continue as it is now or be better off with additional assets like the remaining RPS's with an actual value. There is also the possibility of the RVX IP in their hands. I don't know if there is real interest (DM says there is) out there for an idea like this but if there is and it happens, it would be a huge statement by someone in the know that they strongly believe in the RVX science. The bottom line is that there is no way to finance BoM2 (equity financing is a no go at these prices) except for something like this or a buyout or partnership. We have been hoping for the latter for years to no avail. We need BoM2 to proceed and be successful for the RPS's to be worth anything.
"Now because he can't find money, he's going to screw up Zenith by selling it's royalties on a gamble to pay for the next RVX trial."